Exclusive Summary

• Generic tacrolimus ointment benefits from expired originator patents, ensuring a mature yet growing market, particularly in emerging and price-sensitive regions.
• Stable global demand for atopic dermatitis (AD) treatment, with a large and consistent patient population across all age groups.
• Tacrolimus ointment holds a clear clinical position as a first/second-line treatment for moderate-to-severe AD, especially where corticosteroids are unsuitable, as per major dermatological guidelines.
• Significant cost advantage over the originator drug, enabling competitive pricing and market share gains, supported by robust manufacturing capabilities.
• Chinese suppliers offering internationally certified quality and extensive registration experience can be a key differentiator for global market entry.